UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 194

Sortiert nach

Localization and prediction of malignant potential in recurrent pheochromocytoma/paraganglioma (PCC/PGL) using 18F-FDG PET/CT

Acta radiologica (1987), 2014-06, Vol.55 (5), p.631-640

2014

Volltextzugriff (PDF)

Nephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning. A retrospective analysis

Revista Española de medicina nuclear e imagen molecular (English ed.), 2022-05

2022

Volltextzugriff (PDF)

Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients

The quarterly journal of nuclear medicine and molecular imaging, 2010-02, Vol.54 (1), p.92

2010

Volltextzugriff (PDF)

Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients

The quarterly journal of nuclear medicine and molecular imaging, 2010-02, Vol.54 (1), p.68

2010

Volltextzugriff (PDF)

68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT

European journal of nuclear medicine and molecular imaging, 2013-04, Vol.40 (4), p.514-523

2013

Volltextzugriff (PDF)

Usefulness of combined imaging with 68Ga-DOTATOC PET/CT and spleen scintigraphy in differentiating a neuroendocrine tumour of the pancreatic tail from splenic lesions in a patient with posttraumatic splenosis

Revista Española de medicina nuclear e imagen molecular (English ed.), 2018-09, Vol.37 (5), p.325-327

2018

Volltextzugriff (PDF)

A rare case of a 123I-MIBG SPECT/CT positive, but 68Ga-DOTA-TOC PET/CT negative pheochromocytoma of the bladder

Revista Española de medicina nuclear e imagen molecular (English ed.), 2018-09, Vol.37 (5), p.315-317

2018

Volltextzugriff (PDF)

Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles

International journal of nanomedicine, 2013-01, Vol.8 (1), p.4659-4671

2013

Volltextzugriff (PDF)

Response to "reply to [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al

Neuro-oncology (Charlottesville, Va.), 2013-07, Vol.15 (7), p.814-815

2013

Volltextzugriff (PDF)

super(68)Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT

European journal of nuclear medicine and molecular imaging, 2013-04, Vol.40 (4), p.514-523

2013

Volltextzugriff (PDF)

sup 68^Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT

European journal of nuclear medicine and molecular imaging, 2013-04, Vol.40 (4), p.514

2013

Volltextzugriff (PDF)

68Ga-DOTATOC PET/CT in the localization of metastatic extra-adrenal paraganglioma and pheochromocytoma compared with 18F-DOPA PET/CT

Revista Española de medicina nuclear e imagen molecular (English ed.), 2019-03, Vol.38 (2), p.94-99

2019

Volltextzugriff (PDF)

Individualized molecular cancer therapy based on radiolabelled somatostatin analogues

Memo - Magazine of European medical oncology, 2008-09, Vol.1 (3), p.171-175

2008

Volltextzugriff (PDF)

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

The Journal of nuclear medicine (1978), 2007-04, Vol.48 (4), p.508-518

2007

Volltextzugriff (PDF)

A glioblastoma multiforme patient receiving an intracavitary peptide-receptor-radionuclide-therapy with 90Y-DOTA-TOC: a case report

Memo - Magazine of European medical oncology, 2010-07, Vol.3 (Suppl 3), p.21-24

2010

Volltextzugriff (PDF)

Usefulness of combined imaging with 68 Ga-DOTATOC PET/CT and spleen scintigraphy in differentiating a neuroendocrine tumour of the pancreatic tail from splenic lesions in a patient with posttraumatic splenosis

Revista espanola de medicina nuclear e imagen molecular, 2018-09, Vol.37 (5), p.325

2018

Volltextzugriff (PDF)

A rare case of a 123 I-MIBG SPECT/CT positive, but 68 Ga-DOTA-TOC PET/CT negative pheochromocytoma of the bladder

Revista espanola de medicina nuclear e imagen molecular, 2018-09, Vol.37 (5), p.315

2018

Volltextzugriff (PDF)

Comparison of Folate Receptor Targeted Optical Contrast Agents for Intraoperative Molecular Imaging

International Journal of Molecular Imaging, 2015-01, Vol.2015, p.469047-10

2015

Volltextzugriff (PDF)

99mTechnetium Sestamibi-123Iodine Scintigraphy Is More Accurate Than 99mTechnetium Sestamibi Alone before Surgery for Primary Hyperparathyroidism

International journal of molecular imaging, 2015-01, Vol.2015

2015

Volltextzugriff (PDF)

European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma

European journal of nuclear medicine and molecular imaging, 2019-09, Vol.46 (10), p.2112-2137

2019

Volltextzugriff (PDF)

Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy

Journal of Nuclear Medicine, 2019-04, Vol.60 (4), p.524-529

2019

Volltextzugriff (PDF)

(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

European journal of nuclear medicine and molecular imaging, 2015-07, Vol.42 (8), p.1284-1294

2015

Volltextzugriff (PDF)

Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer

The Journal of nuclear medicine (1978), 2023-06, Vol.64 (6), p.859-862

2023

Volltextzugriff (PDF)

Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the 68 Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer

Journal of Nuclear Medicine, 2023-06, Vol.64 (6), p.859-862

2023

Volltextzugriff (PDF)

[68Ga]NODAGA-RGD – Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis

European journal of nuclear medicine and molecular imaging, 2016-10, Vol.43 (11), p.2005-2013

2016

Volltextzugriff (PDF)

1 – 25 von 194

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(175)
Mit Volltextzugriff
(170)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(92)
Male
(65)
Life Sciences & Biomedicine
(60)
Science & Technology
(60)
Biological And Medical Sciences
(50)
Female
(50)
Middle Aged
(49)
Medical Sciences
(48)
Adult
(36)
Aged
(33)
Oncology
(29)
Nuclear Medicine
(25)
Tumors
(23)
Medicine
(21)
Radiology, Nuclear Medicine & Medical Imaging
(21)
Medicine & Public Health
(20)
Radionuclide Imaging
(20)
Radiopharmaceuticals
(19)
Imaging
(18)
Radiology
(18)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Localization and prediction of malignant potential in recurrent pheochromocytoma/paraganglioma (PCC/PGL) using 18F-FDG PET/CT

Nephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning. A retrospective analysis

Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients

Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients

68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT

Usefulness of combined imaging with 68Ga-DOTATOC PET/CT and spleen scintigraphy in differentiating a neuroendocrine tumour of the pancreatic tail from splenic lesions in a patient with posttraumatic splenosis

A rare case of a 123I-MIBG SPECT/CT positive, but 68Ga-DOTA-TOC PET/CT negative pheochromocytoma of the bladder

Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles

Response to "reply to [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al

super(68)Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT

sup 68^Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT

68Ga-DOTATOC PET/CT in the localization of metastatic extra-adrenal paraganglioma and pheochromocytoma compared with 18F-DOPA PET/CT

Individualized molecular cancer therapy based on radiolabelled somatostatin analogues

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

A glioblastoma multiforme patient receiving an intracavitary peptide-receptor-radionuclide-therapy with 90Y-DOTA-TOC: a case report

Usefulness of combined imaging with 68 Ga-DOTATOC PET/CT and spleen scintigraphy in differentiating a neuroendocrine tumour of the pancreatic tail from splenic lesions in a patient with posttraumatic splenosis

A rare case of a 123 I-MIBG SPECT/CT positive, but 68 Ga-DOTA-TOC PET/CT negative pheochromocytoma of the bladder

Comparison of Folate Receptor Targeted Optical Contrast Agents for Intraoperative Molecular Imaging

99mTechnetium Sestamibi-123Iodine Scintigraphy Is More Accurate Than 99mTechnetium Sestamibi Alone before Surgery for Primary Hyperparathyroidism

European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma

Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy

(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer

Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the 68 Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer

[68Ga]NODAGA-RGD – Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis

Suchergebnisse filtern